
    
      This is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and MTD of TBI
      302 in patients with non-resectable, non-transplantable HCC. Tumor response will be assessed
      at Week 9 (5 weeks following cessation of treatment) according to RECIST (ver 1.1) and AASLD
      criteria.
    
  